Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer

Jen Tsun Lin, Tung Hao Chang, Cheng Shong Chang, Wen Hong Wang, Bi Wen Su, Kuan Der Lee, Pey Jium Chang

Research output: Contribution to journalArticlepeer-review

24 Citations (Scopus)

Abstract

This study investigates the clinical significance of CD44 messenger RNA (mRNA) expression in the peripheral blood of patients with head and neck cancer. Real-time reverse transcriptase-polymerase chain reaction analysis was used to quantify CD44 mRNA levels in the peripheral blood of patients with locally advanced head and neck cancer. All patients were enrolled between January 2006 and December 2008 and had received chemotherapy/radiotherapy for their head and neck cancers. The pretreatment CD44 mRNA levels at a cutoff point of greater than fivefold were associated with an odds ratio of 12.5 for poor prognosis (95% CI, 3.9-40; p < 0.001) and could predict poor treatment response in patients with locally advanced head and neck cancers. Larger prospective studies comparing the current assay with standardized methodologies are warranted.

Original languageEnglish
Pages (from-to)e29-e33
JournalOral Oncology
Volume46
Issue number5
DOIs
Publication statusPublished - May 2010
Externally publishedYes

Keywords

  • CD44 mRNA
  • Head and neck cancer
  • Oral cancer
  • Quantitative RT-PCR

ASJC Scopus subject areas

  • Oral Surgery
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Prognostic value of pretreatment CD44 mRNA in peripheral blood of patients with locally advanced head and neck cancer'. Together they form a unique fingerprint.

Cite this